Using bone marrow and blood to identify specific biomarkers, a new “umbrella” screening study matches patients diagnosed with acute myeloid leukemia (AML) or myeloid dysplastic syndrome (MDS) to one of five clinical trials evaluating precision-medicine therapies from which they might benefit. The MyeloMATCH Master Screening and Reassessment Protocol (MSRP) (NCT05564390) is now recruiting at Roswell Park Comprehensive Cancer Center, led by site Principal Investigator and Chief of Leukemia Eunice Wang, MD.
The five clinical trials, all phase 2, include:
- Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients with High-Risk Acute Myeloid Leukemia (NCT05554406)
- Comparing New Treatments for People with Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (NCT06672146)
- Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) with IDH2 Mutation (NCT06577441)
- Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients with Intermediate-Risk AML (NCT 05554393)
- Venetoclax and HMA Treatment of Older and Unfit Adults with FLT3-Mutated Acute Myeloid Leukemia (AML) (NCT06317649)
Each clinical trial under the umbrella comprises four tiers:
- Tier 1: Induction therapy for newly diagnosed patients
- Tier 2: Treatment for residual disease after initial therapy
- Tier 3: Consolidation therapy or transplant
- Tier 4: Treatment for progressively lower levels of residual disease
At each stage of treatment, re-testing may determine that a patient is eligible to enroll in a higher tier of the same clinical trial. Patients initially screened but not matched with a clinical trial will have the opportunity to continue with standard-of-care treatment while still enrolled in the MSRP so they can retain access to other MyeloMATCH sub-studies.
Sponsored by the National Cancer Institute, MyeloMATCH is directed by the SWOG Cancer Research Network.
Dr. Wang is among the nationally prominent experts who serve on the National Comprehensive Cancer Network (NCCN) Guidelines Panel for acute myeloid leukemia and acute lymphoblastic leukemia, reviewing the latest literature and helping establish a new standard of care for those diseases.
BROADCASTMED